# Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

> **NCT00098618** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **BIOLOGICAL:** recombinant interferon alfa
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00098618
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2006-01
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098618, "Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00098618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*